Literature DB >> 6322210

Brain receptors and zopiclone.

J C Blanchard, A Boireau, L Julou.   

Abstract

Zopiclone (ZPC; RP 27,267), which is chemically unrelated to benzodiazepines (BZD), was found to have a similar pharmacological profile and to possess in man hypnotic activity similar to that of some BZD such as nitrazepam. It was, therefore, interesting to study the interaction of ZPC with rat brain receptors and specially with the so-called 'BZD receptors'. ZPC possesses in three rat brain regions a high affinity for BZD receptors: its Ki values measured against [3H]-flunitrazepam are 24 nM in the cerebral cortex, 31 nM in the cerebellum, and 36 nM in the hippocampus. No other brain receptors such as gamma-aminobutyric acid receptor, dopamine receptor, serotonin and noradrenergic receptors are reached by ZPC. Moreover, ZPC seems to bind only to brain BZD receptors and, contrarily to some BZD such as flunitrazepam, it does not reach the peripheral renal BZD-binding sites. The synthesis of [3H]-ZPC has permitted a more in-depth study of the interaction of ZPC with brain receptors. The high affinity of ZPC has been confirmed by equilibrium-binding studies (KD = 13 +/- 4 nM in rat hippocampus) and the study of the modulating effect of gamma-aminobutyric acid and barbiturates on ZPC binding has revealed some differences between ZPC and BZD. It could, therefore, be postulated that ZPC might bind in rat brain to sites which do not correspond exactly to BZD sites.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6322210     DOI: 10.1159/000137912

Source DB:  PubMed          Journal:  Pharmacology        ISSN: 0031-7012            Impact factor:   2.547


  6 in total

1.  Effects of non-sedative anxiolytic drugs on responses to GABA and on diazepam-induced enhancement of these responses on mouse neurones in cell culture.

Authors:  P P De Deyn; R L Macdonald
Journal:  Br J Pharmacol       Date:  1988-09       Impact factor: 8.739

2.  Modification of GABA turnover in the striatum and hippocampus of the rat after zopiclone.

Authors:  F Zambotti; N Zonta; B Hafner; P Ferrario; L Zecca; P Mantegazza
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1987-05       Impact factor: 3.000

3.  Anxiolytic drugs and the acquisition of conditioned fear in mice.

Authors:  D J Sanger; D Joly
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

Review 4.  Comparative pharmacokinetics and pharmacodynamics of short-acting hypnosedatives: zaleplon, zolpidem and zopiclone.

Authors:  David R Drover
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

Review 5.  Clinical pharmacokinetics of zopiclone.

Authors:  C Fernandez; C Martin; F Gimenez; R Farinotti
Journal:  Clin Pharmacokinet       Date:  1995-12       Impact factor: 6.447

6.  Hypnotic activity of an imidazo-pyridine (zolpidem).

Authors:  A N Nicholson; P A Pascoe
Journal:  Br J Clin Pharmacol       Date:  1986-02       Impact factor: 4.335

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.